1. Pink Sheet
  2. >>Compliance
  3. >>Distribution/Supply Chain

Remdesivir Distribution Begins With More Questions Than Answers

 
• By Sarah Karlin-Smith

Ethicists decry the government's opaque approach, highlighting the potential risks of a fast US FDA emergency authorization if supply isn't able to support demand following regulatory clearance. AmerisourceBergen is distributing the drug for the government, but within the Administration, no agency appears to want to take public responsibility for the decisions about where the doses of the COVID-19 treatment are sent.

Gilead sign at headquarters in Silicon Valley. Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs - Foster City, California, USA - 2020
The benefits of Gilead's speedy emergency use authorization for remdesivir may limited due to limited supply and distribution challenges • Source: Shutterstock

Nearly a week after the US Food and Drug Administration granted an emergency use authorization to Gilead Sciences Inc.’s remdesivir for the treatment of COVID-19 it remains unclear how much drug the US government has access to and how it is deciding where to send the medicine throughout the country.

Based on informally collected data accumulated to try and fill in the gaps from official sources, it appears that the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Distribution/Supply Chain

More from Compliance